Search clinical trials for: Faricimab

Total 26 results

Hoffmann-La Roche

Completed

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
University of Colorado, Denver

Not yet recruiting

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

Diabetic Retinopathy | Vitreous Hemorrhage Due to Diabetes Mellitus
Jaeb Center for Health Research
Juvenile Diabetes Research Foundation; National Eye Institute (NEI); National...

Recruiting

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD (AO)

Neovascular Age-related Macular Degeneration

United States
Medical University of Graz

Active, not recruiting

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (FAN)

Neovascular Age-related Macular Degeneration

Austria
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Vista Klinik

Not yet recruiting

Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept

Diabetic Macular Edema
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

Choroidal Neovascularization Secondary to Pathologic Myopia

Korea, Republic of, China, Australia, Poland, Germany, Taiwan, Hong Kong
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche

Completed

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab (ALTIMETER)

Diabetic Macular Edema

Germany, United States, United Kingdom, Argentina, Canada, Italy, Poland
Greater Houston Retina Research
Genentech, Inc.

Active, not recruiting

Safety and Efficacy of Faricimab in Patients With NPDR (MAGIC)

Non-Proliferative Diabetic Retinopathy

United States
McMaster University
Hoffmann-La Roche

Recruiting

Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial (INSITE-DME)

Diabetic Macular Edema

Australia, United States, Canada, United Kingdom
Nantes University Hospital
Rennes University Hospital

Not yet recruiting

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (FAR-WEST)

AMD

France
Genentech, Inc.

Recruiting

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

Diabetic Macular Edema

United States, Puerto Rico, Kenya, India
Hoffmann-La Roche

Completed

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (BOULEVARD)

Diabetic Macular Edema

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, Japan, Canada, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Singapore, Czechia, Hong Kong, Israel, Portugal, Russian Federation and more
Hoffmann-La Roche

Completed

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) (AVENUE)

Choroidal Neovascularization

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Diabetic Macular Edema

United States, Japan, Israel, Austria, France, Germany, Hungary, Italy, Mexico, Poland, Slovakia, Spain, Russian Federation, Bulgaria, Turkey, Peru
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

Diabetic Macular Edema

Korea, Republic of, United States, United Kingdom, Brazil, China, Canada, Argentina, Australia, Denmark, France, Italy, Poland, Spain, Germany, Singapore, Czechia, Hong Kong, Portugal, Russian Federation, Taiwan, Hungary, Switzerland and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Neovascular Age-related Macular Degeneration

United States, Korea, Republic of, United Kingdom, Japan, Canada, Turkey, Argentina, Australia, Denmark, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Israel, Portugal, Russian Federation, Ta... and more
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Germany, Japan, United Kingdom, Spain, United States, Italy, Switzerland, Canada, France, Australia, Singapore, Puerto Rico, United Arab Emirates, Bulgaria, Croatia, Chile
Rigshospitalet, Denmark

Completed

Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Neovascular Age-related Macular Degeneration

Denmark
Rigshospitalet, Denmark

Completed

Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Neovascular Age-related Macular Degeneration

Denmark
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Wet Macular Degeneration

United Kingdom, Germany, Japan, Netherlands, United States, Canada, Hungary, Italy, Mexico, Poland, Spain, Israel, Russian Federation, Switzerland, Turkey
Hoffmann-La Roche

Completed

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (STAIRWAY)

Macular Degeneration, Age-Related | Neovascularization, Choroidal

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Wet Macular Degeneration

Korea, Republic of, United States, China, Argentina, Australia, Denmark, France, Germany, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Hungary, Portugal, Russian Federation, Taiwan, Turkey, Bulgaria
Jaeb Center for Health Research
National Eye Institute (NEI); Genentech, Inc.; National Institutes of Health... and other collaborators

Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy (AL)

Visual Impairment | Radiation Retinopathy

United States

Search clinical trials for: Faricimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations